Supplementary figure 1. Global clinical trials included in 'All Exposure' analysis

Trial	Description
DANCER	Dose-ranging Assessment: International Clinical Evaluation of Rituximab in Rheumatoid Arthritis. WA17043/U2644g; A randomised, multifactorial, double-blind, parallel-group, dose-ranging study of the efficacy and safety of rituximab (MabThera®/Rituxan®) in combination with methotrexate in patients with active RA.
IMAGE	WA17047/U3373g; A randomised, phase III, controlled, double-blind, parallel-group, multicentre study to evaluate the safety and efficacy of rituximab in combination with methotrexate (MTX) compared to MTX alone, in methotrexate-naïve patients with active RA.
MIRROR	WA17044/U2974g; A randomised, double-blind, international study to evaluate the efficacy and safety of various re-treatment regimens of rituximab in combination with methotrexate in RA patients with an inadequate response to methotrexate.
REFLEX	A Randomised Evaluation of Long-term Efficacy of Rituximab in RA. WA17042/IDEC 102-20: A randomised, placebo controlled, double-blind, multicentre study to evaluate the safety and efficacy of rituximab in combination with methotrexate in patients with active RA who have had an inadequate response to anti-TNF therapies.
SERENE	WA17045/U2973g; A randomised, placebo controlled, double-blind, parallel-group, international study to evaluate the safety and efficacy of rituximab in combination with methotrexate, compared with methotrexate monotherapy, in patients with active RA.
SIERRA	U3374g; A phase II, randomised, parallel-group, open-label, multicentre study to evaluate the effects of rituximab on immune responses in subjects with active RA receiving background methotrexate.
SUNRISE	U3384g; A phase III, randomised, double-blind, placebo-controlled, multicentre study of retreatment with rituximab in subjects with RA receiving background methotrexate.
WA16291	A randomized, double-dummy, controlled, parallel-group study of the efficacy and safety of MabThera® (rituximab) alone or in combination with either cyclophosphamide or methotrexate, in patients with RA.
WA16855	Open-label extension study for DANCER and WA16291 WA16855/U2653g; An open-label study of the efficacy and safety of re-treatments with rituximab (MabThera®/Rituxan®) in patients with active RA.
WA17531	Open-label extension study for REFLEX WA17531/IDEC-102-21; An open-label study of the efficacy and safety of re-treatments with rituximab (MabThera®/Rituxan®) in patients with active RA who have had an inadequate response to anti-TNFα therapies.

Supplementary figure 2. Disposition of patients over treatment courses 1 to 17



Patients who received a repeat treatment course are indicated:

*Remained in study on this current course at the time of the datacut.
**Withdrawal for reasons other than AE. 'Other' includes insufficient therapeutic response, failure to return, violation of selection criteria at entry, other protocol violation, refused treatment/did not cooperate, withdrew consent, administrative/other (including patient entry to extension protocols), lost to follow-up, physician's decision to withdraw, and pregnancy.
***After courses 1 and 2, patients from SUNRISE and SIERRA were not offered additional courses of rituximab per protocol, and are shown here. Patients in all other studies who completed the initial treatment period but did not enter extension protocols are classed as completers for their initial study protocol.